Licensing agreement for Captisol-enabled intravenous formulation of clopidogrelLicensing Agreement • January 28th, 2022 • New Jersey
Contract Type FiledJanuary 28th, 2022 JurisdictionLigand has licensed exclusive worldwide rights to The Medicines Company for Ligand’s Captisol-enabled intravenous formulation of clopidogrel.
Licensing agreement for Captisol-enabled intravenous formulation of clopidogrelLicensing Agreement • January 28th, 2022 • New Jersey
Contract Type FiledJanuary 28th, 2022 JurisdictionLigand has licensed exclusive worldwide rights to The Medicines Company for Ligand’s Captisol-enabled intravenous formulation of clopidogrel.